1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Diffusion and perfusion results in patients <6 months from RTa
Treatment-Related Change (Median) Recurrent Tumor (Median) P Value Survival Analysis HR P Value ADCLesion 0.00162 0.00139 .001b 5.563 .047b ADCROI 0.0012 0.0011 .128 0.653 .651 ADCRatio 1.585 1.482 .288 0.703 .595 rCBVLesion 0.88 1.76 .028b 1.382 .233 rCBVROI 1.625 2.575 .032b 1.563 .009b PSRROI 0.80 0.87 .467 0.166 .040b